MA40921A - Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation - Google Patents

Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation

Info

Publication number: MA40921A
Authority: MA; Morocco
Prior art keywords: chemerical; cldn; receptors; genetic; methods
Prior art date: 2014-11-05

Application number

MA040921A

Other languages

English (en)

Inventor

Scott J Dylla

Paul Anthony Escarpe

David Liu

Robert A Stull

Original Assignee

Abbvie Stemcentrx Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-11-05

Filing date

2015-11-03

Publication date

2017-09-12

2014-11-05 Priority claimed from PCT/US2014/064165 external-priority patent/WO2015069794A2/fr

2015-11-03 Application filed by Abbvie Stemcentrx Llc filed Critical Abbvie Stemcentrx Llc

2017-09-12 Publication of MA40921A publication Critical patent/MA40921A/fr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells

MA040921A 2014-11-05 2015-11-03 Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation MA40921A (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
PCT/US2014/064165 WO2015069794A2 (fr)	2013-11-06	2014-11-05	Nouveaux anticorps anti-claudine et leurs méthodes d'utilisation
US201562157928P	2015-05-06	2015-05-06
US201562247108P	2015-10-27	2015-10-27

Publications (1)

Publication Number	Publication Date
MA40921A true MA40921A (fr)	2017-09-12

Family

ID=55909771

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA040921A MA40921A (fr)	2014-11-05	2015-11-03	Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation

Country Status (23)

Country	Link
US (1)	US20170334991A1 (fr)
EP (1)	EP3215523A4 (fr)
JP (1)	JP2017535283A (fr)
KR (1)	KR20170085531A (fr)
CN (1)	CN107207580A (fr)
AU (1)	AU2015343079A1 (fr)
BR (1)	BR112017009517A2 (fr)
CA (1)	CA2966618A1 (fr)
CL (1)	CL2017001118A1 (fr)
CO (1)	CO2017005538A2 (fr)
CR (1)	CR20170235A (fr)
DO (1)	DOP2017000110A (fr)
EA (1)	EA201790967A1 (fr)
EC (1)	ECSP17031725A (fr)
IL (1)	IL252090A0 (fr)
MA (1)	MA40921A (fr)
MX (1)	MX2017005797A (fr)
PE (1)	PE20171060A1 (fr)
PH (1)	PH12017500825A1 (fr)
SG (1)	SG11201703669YA (fr)
TW (1)	TW201625677A (fr)
WO (1)	WO2016073649A1 (fr)
ZA (1)	ZA201703471B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2015069794A2 (fr) *	2013-11-06	2015-05-14	Stem Centrx, Inc.	Nouveaux anticorps anti-claudine et leurs méthodes d'utilisation
JP2019530706A (ja) *	2016-10-14	2019-10-24	メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋＳｈａｒｐ＆ＤｏｈｍｅＣｏｒｐ．	尿路上皮がんを治療するための、ｐｄ−１アンタゴニスト及びエリブリンの組合せ
TW202405006A (zh)	2017-09-29	2024-02-01	日商第一三共股份有限公司	抗體－吡咯并苯二氮呯衍生物複合體
WO2020114518A1 (fr) *	2018-12-07	2020-06-11	科济生物医药（上海）有限公司	Polyimmunothérapie anti-tumorale
JP2022524906A (ja) *	2019-01-07	2022-05-11	クレージュメディカルカンパニー，リミテッド	細胞免疫療法の組み合わせ
US20210347847A1 (en) *	2020-05-11	2021-11-11	The Broad Institute, Inc.	Therapeutic targeting of malignant cells using tumor markers
JP2024500847A (ja)	2020-12-18	2024-01-10	センチュリーセラピューティクス，インコーポレイテッド	適合可能な受容体特異性を有するキメラ抗原受容体システム
JP2024512337A (ja) *	2021-03-05	2024-03-19	シャンハイ、ケンパーソー、バイオテクノロジー、カンパニー、リミテッド	抗ｃｌｄｎ６抗体およびその使用
CN114478802B (zh) *	2022-01-28	2023-05-26	郑州大学	一种嵌合抗原受体及其应用
WO2024088325A1 (fr) *	2022-10-25	2024-05-02	科济生物医药（上海）有限公司	Anticorps et son utilisation
CN117169518B (zh) *	2023-11-03	2024-01-19	赛德特(北京)生物工程有限公司	T淋巴细胞制剂中的cd3抗体残留物的检测方法和试剂盒

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN101074261A (zh) *	2006-04-30	2007-11-21	北京同为时代生物技术有限公司	Trail受体1和/或trail受体2特异性抗体及其应用
US8192740B2 (en) *	2007-02-27	2012-06-05	Forerunner Pharma Research Co., Ltd.	Pharmaceutical composition comprising anti-GRP78 antibody as active ingredient
US9274119B2 (en) *	2008-01-11	2016-03-01	The University Of Tokyo	Anti-CLDN6 antibody
HUE049404T2 (hu) *	2009-11-11	2020-09-28	Astellas Pharma Inc	CLAUDIN 6 (CLDN6)-specifikus antitestek
EP2404936A1 (fr) *	2010-07-06	2012-01-11	Ganymed Pharmaceuticals AG	Thérapie du cancer utilisant des anticorps in vivo dirigés sur la cible CLDN6
EP3623380A1 (fr) *	2013-03-15	2020-03-18	Michael C. Milone	Ciblage de cellules cytotoxiques avec récepteurs chimériques pour immunothérapie adoptive
WO2015069794A2 (fr) *	2013-11-06	2015-05-14	Stem Centrx, Inc.	Nouveaux anticorps anti-claudine et leurs méthodes d'utilisation
PT3126381T (pt) *	2014-04-01	2019-04-18	Ganymed Pharmaceuticals Ag	Imunorrecetores e epítopos de células t específicos da claudina-6
WO2016180467A1 (fr) *	2015-05-11	2016-11-17	Biontech Cell & Gene Therapies Gmbh	Renforcement de l'effet de lymphocytes t génétiquement modifiés par car, par vaccination par acide nucléique
CN108473588A (zh) *	2015-12-04	2018-08-31	艾伯维施特姆森特克斯有限责任公司	新颖抗密封蛋白抗体及使用方法

2015
- 2015-11-03 MA MA040921A patent/MA40921A/fr unknown
- 2015-11-04 EA EA201790967A patent/EA201790967A1/ru unknown
- 2015-11-04 CA CA2966618A patent/CA2966618A1/fr not_active Abandoned
- 2015-11-04 WO PCT/US2015/059106 patent/WO2016073649A1/fr active Application Filing
- 2015-11-04 PE PE2017000813A patent/PE20171060A1/es not_active Application Discontinuation
- 2015-11-04 KR KR1020177015413A patent/KR20170085531A/ko unknown
- 2015-11-04 MX MX2017005797A patent/MX2017005797A/es unknown
- 2015-11-04 CN CN201580072018.5A patent/CN107207580A/zh active Pending
- 2015-11-04 CR CR20170235A patent/CR20170235A/es unknown
- 2015-11-04 AU AU2015343079A patent/AU2015343079A1/en not_active Abandoned
- 2015-11-04 SG SG11201703669YA patent/SG11201703669YA/en unknown
- 2015-11-04 BR BR112017009517A patent/BR112017009517A2/pt not_active Application Discontinuation
- 2015-11-04 JP JP2017543306A patent/JP2017535283A/ja active Pending
- 2015-11-04 US US15/524,675 patent/US20170334991A1/en not_active Abandoned
- 2015-11-04 EP EP15857690.0A patent/EP3215523A4/fr not_active Withdrawn
- 2015-11-05 TW TW104136552A patent/TW201625677A/zh unknown
2017
- 2017-05-02 DO DO2017000110A patent/DOP2017000110A/es unknown
- 2017-05-03 IL IL252090A patent/IL252090A0/en unknown
- 2017-05-04 PH PH12017500825A patent/PH12017500825A1/en unknown
- 2017-05-05 CL CL2017001118A patent/CL2017001118A1/es unknown
- 2017-05-19 ZA ZA2017/03471A patent/ZA201703471B/en unknown
- 2017-05-25 EC ECIEPI201731725A patent/ECSP17031725A/es unknown
- 2017-06-02 CO CONC2017/0005538A patent/CO2017005538A2/es unknown

Also Published As

Publication number	Publication date
ZA201703471B (en)	2019-06-26
TW201625677A (zh)	2016-07-16
MX2017005797A (es)	2017-10-23
CR20170235A (es)	2017-07-21
SG11201703669YA (en)	2017-06-29
DOP2017000110A (es)	2017-05-31
JP2017535283A (ja)	2017-11-30
BR112017009517A2 (pt)	2017-12-19
CA2966618A1 (fr)	2016-05-12
WO2016073649A1 (fr)	2016-05-12
EP3215523A4 (fr)	2018-06-20
EA201790967A1 (ru)	2017-10-31
CO2017005538A2 (es)	2017-10-10
IL252090A0 (en)	2017-07-31
PH12017500825A1 (en)	2017-10-18
CL2017001118A1 (es)	2018-01-05
AU2015343079A1 (en)	2017-05-25
CN107207580A (zh)	2017-09-26
ECSP17031725A (es)	2017-06-30
US20170334991A1 (en)	2017-11-23
KR20170085531A (ko)	2017-07-24
PE20171060A1 (es)	2017-07-21
EP3215523A1 (fr)	2017-09-13

Publication	Publication Date	Title
FR23C1004I2 (fr)	2024-01-05	Antagonistes du fcrn et procédés d'utilisation
IL279606A (en)	2021-03-01	Anti-TREM2 antibodies and methods of using them
MA51552A (fr)	2021-03-24	Anticorps anti-ox40 et procédés d'utilisation
HK1243102A1 (zh)	2018-07-06	抗cd79b抗體和使用方法
MA44524A (fr)	2019-02-06	Néoantigènes et leurs procédés d'utilisation
MA43018A (fr)	2021-06-02	Anticorps anti-pd1 et procédés d'utilisation
HRP20181359T1 (hr)	2018-10-19	Anti-jagged1 protutijela i postupci uporabe
MA47849A (fr)	2020-01-29	Anticorps anti-gitr et leurs procédés d'utilisation
MA40921A (fr)	2017-09-12	Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation
MA43380A (fr)	2018-10-10	Récepteurs chimériques modifiés et compositions et procédés associés
MA42043A (fr)	2018-03-14	Anticorps anti-ox40 et procédés d'utilisation de ceux-ci
KR20180084817A (ko)	2018-07-25	항-siglec-9 항체 및 이의 이용 방법
DK3149042T3 (da)	2019-11-04	PD-L1-antistoffer og anvendelser deraf
DK3227342T4 (da)	2023-07-10	Proteinøs heterodimer og anvendelse deraf
MA55097A (fr)	2022-01-05	Oxystérols et leurs procédés d'utilisation
HUE047784T2 (hu)	2020-05-28	Anti-TIM3 antitestek és alkalmazási eljárások
MA41613A (fr)	2018-01-02	Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs
DK3126381T4 (da)	2022-04-04	Claudin-6-specifikke immunoreceptorer og t-celleepitoper
MA42409A (fr)	2018-05-16	Oxystérols et leurs procédés d'utilisation
MA54851A (fr)	2021-12-08	Oxystérols et leurs procédés d'utilisation
MA40933A (fr)	2017-09-19	Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines
DK3233903T3 (da)	2021-02-22	Kimære antigenreceptorer og anvendelsesfremgangsmåder
MA39915B1 (fr)	2019-05-31	Composés de pladiénolide pyridine et leurs procédés d'utilisation
MA40759A (fr)	2017-08-01	Modulateurs de rorc2 de type pyrrolopyridine substitué par un méthyle et trifluorométhyle et leurs procédés d'utilisation
MA44087A (fr)	2018-10-24	Immunothérapie basée sur la listéria et ses méthodes d'utilisation